Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Savara Inc.

< Previous 1 2 Next >
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Participation in Upcoming Healthcare Conferences
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Host Analyst and Investor Webinar on September 30, 2024
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at the Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at the Citizens JMP Life Sciences Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.